ERBB2 and non-small cell lung carcinoma: (73) have developed a trastuzumab-modified, mannosylated liposome system that effectively targets M2-type TAMs and HER-2 positive NSCLC cells to overcome EGFR-TKIs resistance mediated by the EGFR T790M mutation.